the lysates preferably containing chaperone proteins, and such lysates formulated with an aliquot of allogeneic cells (same cells used to prime the patient) to create a rejection response and stimulate a delayed-type hypersensitivity response to the alloantigens which serve to adjuvant the stimulation of systemic anti-tumor or anti-pathogen immunity. In a further embodiment, this method may be practiced without the priming step.

[0010a] In one aspect, there is provided a therapeutic composition for use in treating a tumor or pathogen in a patient comprising: allogeneic cells; and antigens comprising the product of tumor necrosis or pathogen infected tissue necrosis, wherein the antigens are generated in situ, whereby the allogeneic cells and the in situ generated antigens elicit an immune response by the patient to create an anti-tumor or anti-pathogen immunity.

[0011] In another embodiment, the present disclosure includes a therapeutic composition for treating a tumor or a pathogen in a patient comprising tumor antigens or pathogen antigens generated *in situ* and allogeneic cells, wherein the allogeneic cells and the *in situ* generated antigens elicit an immune response whereby subsequent maturation of the patient's antigen presenting cells systemically stimulate anti-tumor or anti pathogen immunity. The tumor antigens or pathogen antigens are generated *in situ* from necrosis of the tumor or the pathogen infected tissue. The therapeutic composition may also include a priming composition containing allogeneic cells. The allogeneic cells in the priming composition and in the antigenic composition may include between about 1×10^8 and about 1×10^{10} cells.

[0011a] In one aspect, there is provided a vaccine composition comprising: an adjuvant comprising allogeneic cells; and antigens generated in situ by necrosis of diseased cells or tissue, wherein the presence of the adjuvant at the necrotic site along with the in situ generated antigens elicit an immune response by the patient to create immunity against the disease.

WHAT IS CLAIMED IS:

1. A therapeutic composition for use in treating a tumor or pathogen in a patient comprising:

allogeneic cells; and

antigens comprising the product of tumor necrosis or pathogen infected tissue necrosis, wherein the antigens are generated *in situ*, whereby the allogeneic cells and the *in situ* generated antigens elicit an immune response by the patient to create an anti-tumor or anti-pathogen immunity.

2. A vaccine composition comprising:

an adjuvant comprising allogeneic cells; and

antigens generated *in situ* by necrosis of diseased cells or tissue, wherein the presence of the adjuvant at the necrotic site along with the *in situ* generated antigens elicit an immune response by the patient to create immunity against the disease.

3. The composition of claims 1 and 2 further comprising a priming composition wherein the priming composition comprises allogeneic cells.

4. The composition of claims 1 and 2 wherein the antigens are generated *in situ* by ablation of the tumor or pathogen infected tissue.

5. The composition of claim 4 wherein the ablation is by cryoablation.

6. The composition of claim 4 wherein the ablation is by electroporation.

7. The composition of claims 1 and 2 wherein the antigens comprise tumor or pathogen antigens, heat shock proteins and combinations thereof.

8. The composition of claims 1 and 2 wherein the allogeneic cells are activated T-cells.

9. The composition of claims 1 and 2 wherein the allogeneic cells express high levels of Type 1 cytokines.

10. The composition of claims 1 and 2 wherein the allogeneic cells express a high density of CD40L, TRAIL, FasL and combinations thereof on the cell surface.

11. Use of allogeneic cells in the manufacture of a medicament for inducing an adaptive immune response against a tumor or a pathogen in a patient, wherein the allogeneic cells are to be administered to be directed to the site of antigens generated in situ from the disease or pathogen infection, to thereby create an immune response that serves as an adjuvant to the uptake of antigens from the ablated tissue whereby subsequent maturation of the patient's antigen presenting cells systemically stimulate anti-tumor or anti-pathogen immunity.

12. The use of claim 11, wherein

a priming composition is to be administerd to a patient prior to the generation of antigens *in situ*, the priming composition comprising allogeneic T-cells to be rejected by the patient's immune system in a manner that induces an allogeneic Th1 immunity ; and

permitting the patient's immune system to form anti-allogeneic Th1 immune memory prior to the generation of *in situ* antigens.

13. The use of claim 11 wherein the antigens are generated *in situ* by ablation of the tumor or pathogen infected tissue.

14. The ~~method~~ use of claim 13 wherein the ablation is by cryoablation.

15. The use of claim 13 wherein the ablation is by electroporation.

16. The use of claim 11 wherein the antigens comprise tumor or pathogen antigens, heat shock proteins and combinations thereof.

17. The use of claim 11 wherein the allogeneic cells are allogeneic T-cells.

18. The use of claim 11 wherein the allogeneic cells express high levels of Type 1 cytokines.

19. The use of claim 11 wherein the allogeneic cells express a high density of CD40L, TRAIL, FasL and combinations thereof on the cell surface.